The Alliance of Community Health Plans (ACHP) sent a letter to key Congressional committee leaders urging hearings on the high-cost cell and gene therapies rapidly gaining FDA approval. ACHP recognizes that these new treatments will require changes to how we think about coverage and payment and calls on Congress to engage to balance the need for patient access with the high up-front prices of these therapies.
New from ACHP:
- ACHP Statement on Budget Reconciliation Bill
- ACHP Recommendations on Prescription Drug Machine-Readable File Requirement in Coverage Final Rule
- ACHP Opposes Senate Reconciliation Bill That Threatens Coverage for Millions
- ACHP Recommendations to Strengthen CMS Drug Price Negotiation Guidance for 2028
- GLP-1s Are Not A Silver Bullet
- Local Health Plans Meet Community Needs with Affordable, Accessible Vaccines
